Status: Recommended with restrictions | ||
Teriflunomide (AUBAGIO®) is recommended as an option for restricted use within NHS Wales. Teriflunomide (AUBAGIO®) is licensed for the treatment of paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis. Teriflunomide (AUBAGIO®) is restricted for use for the treatment of active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years) in paediatric patients aged 10 years and older, who do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
||
|
||
Medicine details |
||
Medicine name | teriflunomide (AUBAGIO®) | |
Formulation | 7 mg and 14 mg tablet | |
Reference number | 4033 | |
Indication | Treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years |
|
Company | Aventis Pharma Ltd | |
BNF chapter | Malignant disease & immunosuppression | |
Submission type | Licence extension for paediatric use | |
Status | Recommended with restrictions | |
Advice number | 1022 | |
AWMSG meeting date | 27/04/2022 | |
Date of issue | 12/05/2022 | |
NICE guidance | TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis in adults |
|
Commercial arrangement | PAS |